Evidence map›Paper›PMID 33042439›Full record

ArticleAmerican journal of translational research2020

MiR-125b-2-3p associates with prognosis of ccRCC through promoting tumor metastasis via targeting EGR1.

Xiangyu Meng, Kaitai Liu, Zhenfei Xiang, Xiao Yu, Ping Wang, Qi Ma

Abstract read
In one paragraph

Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Frontiers in cell and developmental biology · 2021
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiangyu MengTranslational Research Laboratory for Urology, The Key Laboratory of Ningbo City, Ningbo First Hospital, The Affliated Hospital of Ningbo University #59 Liuting Street, Ningbo 315010, China.
Kaitai LiuNingbo City Medical Treatment Center Lihuili Hospital #57 Xingning Street, Ningbo 315040, China.
Zhenfei XiangNingbo City Medical Treatment Center Lihuili Hospital #57 Xingning Street, Ningbo 315040, China.
Xiao YuMedical School, Ningbo University #818 Fenghua Road, Ningbo 315211, China.
Ping WangMedical School, Ningbo University #818 Fenghua Road, Ningbo 315211, China.
Qi MaTranslational Research Laboratory for Urology, The Key Laboratory of Ningbo City, Ningbo First Hospital, The Affliated Hospital of Ningbo University #59 Liuting Street, Ningbo 315010, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is an aggressive tumor with frequent metastatic rate. In order to explore the mechanisms, we determined the roles of miR-125b-2-3p in metastatic ccRCC progression. In the study, both clinical and experimental evidences supported the critical role of miR-125b-2-3p in accelerating ccRCC metastasis. Elevated miR-125b-2-3p expression correlated with lymphatic invasion, distant metastasis and poor survival. Functional study showed that high miR-125b-2-3p expression significantly increased ccRCC cell migration

Indexed as

ccRCCEGR1metastasismiR-125b-2-3pprognosis

Identifiers

PMID33042439
PMCPMC7540096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.